MSR1 and glioblastoma: There was no significant difference in RFI between treatment with TMZ and TMZ with additional adjuvants (p = 0.50) in glioblastoma cases with a high expression of CD204+TAMs and a low expression of CD4+TILs (Fig. 6b).